Cervical cancer biomarker enters trials:
This article was originally published in Clinica
A US clinical trial will examine cervical cancer smears for telomerase, a protein released into cells to help repair damaged chromosomes, to see whether the marker can predict women at highest risk of cancer. Researchers from the University of North Carolina at Chapel Hill hope to correlate "the genetics of a normal biopsy with the expression of telomerase in Pap smears". If this is the case, telomerase expression would indicate treatable genetically altered cells, while no expression would indicate with greater certainty that treatment is not necessary.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.